logo

For the Inventor, By the Inventor

Aachen, Germany

Grunenthal Gmbh

Calculating rank
USPTO Granted Patents = 107

% Expired Patents = 61.7



Forward Citations = 1,021

Loading Chart...
Loading Chart...

186 inventors (with patents filed for the assignee):

goldMedal Johannes Bartholomäus (18 out of 28 patents)

silverMedal Florian Jakob (15 out of 27 patents)

bronzeMedal Heinrich Kugelmann (14 out of 22 patents)

4.  Lutz Barnscheid (13 out of 18 patents)

5.  Achim Kless (12 out of 30 patents)

6.  Stefan Schunk (12 out of 36 patents)

7.  Paul Ratcliffe (11 out of 15 patents)

8.  Ingo Konetzki (10 out of 16 patents)

9.  Wolfgang Schröder (10 out of 25 patents)

10.  Sebastian Schwier (9 out of 12 patents)

11.  Tobias Craan (9 out of 14 patents)

12.  Melanie Reich (8 out of 34 patents)

13.  Gregor Bahrenberg (8 out of 46 patents)

14.  Simon Lucas (8 out of 12 patents)

15.  Werner Guenter Englberger (8 out of 58 patents)


Core Competencies:
Tamper Resistant
Abuse-Proofed
Pharmaceutical Dosage Forms
Pain Treatment
Triazolo Quinoxaline
Pyrazole Amides
KCNQ2/3 Modulators
Stable Formulations
Chronic Pain Inhibition
Crystallization Methods
Drug Release
Formulation Stability

107 patents:

1. 12358907 - Substituted pyrrolidine amides III (2025-07-15),
2. 12110293 - Substituted triazolo quinoxaline derivatives (2024-10-08),
3. 11999699 - Substituted pyrazole amides (2024-06-04),
4. 11981677 - Further substituted triazolo quinoxaline derivatives (2024-05-14),
5. 11844865 - Abuse-proofed oral dosage form (2023-12-19),
6. 11739049 - Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol (2023-08-29),
7. 11344512 - Titration of tapentadol (2022-05-31),
8. 11224576 - Process for the production of an abuse-proofed dosage form (2022-01-18),
9. 11013701 - Stable formulation for parenteral administration of tapentadol (2021-05-25),
10. 10981918 - Further substituted triazolo quinoxaline derivatives (2021-04-20),
11. 10912763 - Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine (2021-02-09),
12. 10864164 - Tamper-resistant tablet providing immediate drug release (2020-12-15),
13. 10842750 - Protecting oral overdose with abuse deterrent immediate release formulations (2020-11-24),
14. 10813891 - Method of inhibiting chronification of pain (2020-10-27),
15. 10813890 - Pharmaceutical combination (2020-10-27),
Company Overview
Grunenthal GmbH, headquartered in Aachen, Germany, specializes in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on creating tamper-resistant and abuse-proofed dosage forms, particularly in the realm of pain treatment. Grunenthal's research encompasses advanced technologies such as triazolo quinoxaline and pyrazole amides, as well as KCNQ2/3 modulators, aimed at delivering stable formulations that enhance patient safety and therapeutic efficacy.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

Grunenthal Gmbh USPTO Patent Assignee Logo
107 Patents

#4 in Aachen

#559 in Germany

#7,356 in the World

Aachen, DE
Aachen, Germany

Grunenthal Gmbh

Forward Citations = 1,021

186 inventors:

goldMedal Johannes Bartholomäus (18 out of 28 patents)

silverMedal Florian Jakob (15 out of 27 patents)

bronzeMedal Heinrich Kugelmann (14 out of 22 patents)

4.  Lutz Barnscheid (13 out of 18 patents)

5.  Achim Kless (12 out of 30 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Grunenthal Gmbh. Retrieved from https://idiyas.com/company/grunenthal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…